320 related articles for article (PubMed ID: 33500640)
1. Long-Term Outcomes of Previously Treated Adult and Adolescent Patients with Severe Hemophilia A Receiving Prophylaxis with Extended Half-Life FVIII Treatments: An Economic Analysis from a United Kingdom Perspective.
Benson G; Morton T; Thomas H; Lee XY
Clinicoecon Outcomes Res; 2021; 13():39-51. PubMed ID: 33500640
[TBL] [Abstract][Full Text] [Related]
2. Clinical efficacy of simoctocog alfa versus extended half-life recombinant FVIII concentrates in hemophilia A patients undergoing personalized prophylaxis using a matching-adjusted indirect comparison method.
Kessler CM; Corrales-Medina FF; Mannucci PM; Jiménez-Yuste V; Tarantino MD
Eur J Haematol; 2023 Nov; 111(5):757-767. PubMed ID: 37587687
[TBL] [Abstract][Full Text] [Related]
3. A Retrospective Observational Study of Rurioctocog Alfa Pegol in Clinical Practice in the United States.
Aledort L; Milligan S; Watt M; Booth J
J Manag Care Spec Pharm; 2020 Apr; 26(4):492-503. PubMed ID: 32223610
[TBL] [Abstract][Full Text] [Related]
4. Efmoroctocog Alfa: A Review in Haemophilia A.
Frampton JE
Drugs; 2021 Nov; 81(17):2035-2046. PubMed ID: 34743314
[TBL] [Abstract][Full Text] [Related]
5. Turoctocog alfa pegol provides effective management for major and minor surgical procedures in patients across all age groups with severe haemophilia A: Full data set from the pathfinder 3 and 5 phase III trials.
Tosetto A; Neff A; Lentz SR; Santagostino E; Nemes L; Sathar J; Meijer K; Chowdary P; Shen C; Landorph A; Hampton K
Haemophilia; 2020 May; 26(3):450-458. PubMed ID: 32293786
[TBL] [Abstract][Full Text] [Related]
6. Clinical studies of extended-half-life recombinant FVIII products for prophylaxis in adults and children: A critical review from the physician's perspective.
Hermans C; Reding MT; Astermark J; Klamroth R; Mancuso ME
Crit Rev Oncol Hematol; 2022 Jun; 174():103678. PubMed ID: 35390452
[TBL] [Abstract][Full Text] [Related]
7. Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A.
Solms A; Shah A; Berntorp E; Tiede A; Iorio A; Linardi C; Ahsman M; Mancuso ME; Zhivkov T; Lissitchkov T
Ann Hematol; 2020 Nov; 99(11):2689-2698. PubMed ID: 32974838
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety and efficacy results from the phase 3b, open-label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A.
Chowdary P; Mullins ES; Konkle BA; McGuinn C; Park YS; Stasyshyn O; Zulfikar B; Engl W; Tangada S
Haemophilia; 2020 Jul; 26(4):e168-e178. PubMed ID: 32597029
[TBL] [Abstract][Full Text] [Related]
9. Microsimulation to compare activity-related bleed risks between pharmacokinetic-guided rurioctocog alfa pegol prophylaxis and emicizumab.
Sun SX; Crawford S
Expert Rev Hematol; 2023 Mar; 16(3):205-211. PubMed ID: 36655343
[TBL] [Abstract][Full Text] [Related]
10. Canadian clinical experience on switching from standard half-life recombinant factor VIII (rFVIII), octocog alfa, to extended half-life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in Canada.
Matino D; Germini F; Chan AKC; Decker K; Iserman E; Chelle P; Edginton AN; Oladoyinbo O; Trinari E; Keepanasseril A; Iorio A
Haemophilia; 2024 Mar; 30(2):345-354. PubMed ID: 38379181
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of damoctocog alfa pegol prophylaxis in patients with severe haemophilia A: Results of an interventional, post-marketing study.
Holme PA; Poulsen LH; Tueckmantel C; Maas Enriquez M; Alvarez Román MT; De Cristofaro R
Haemophilia; 2024 Mar; 30(2):388-394. PubMed ID: 38229269
[TBL] [Abstract][Full Text] [Related]
12. Damoctocog Alfa Pegol: A Review in Haemophilia A.
Paik J; Deeks ED
Drugs; 2019 Jul; 79(10):1147-1156. PubMed ID: 31218660
[TBL] [Abstract][Full Text] [Related]
13. Indirect Treatment Comparison of Damoctocog Alfa Pegol versus Turoctocog Alfa Pegol as Prophylactic Treatment in Patients with Hemophilia A.
Vashi P; Batt K; Klamroth R; Mancuso ME; Majewska R; Tiede A; Mantovani LG
J Blood Med; 2021; 12():935-943. PubMed ID: 34754257
[TBL] [Abstract][Full Text] [Related]
14. Damoctocog Alfa Pegol for Hemophilia A Prophylaxis: An Italian Multicenter Survey.
Zanon E
Pharmaceuticals (Basel); 2023 Aug; 16(9):. PubMed ID: 37765002
[TBL] [Abstract][Full Text] [Related]
15. Real-world study of rurioctocog alfa pegol and emicizumab in US clinical practice among patients with hemophilia A.
Sun SX; Frick A; Balasa V; Roberts JC
Expert Rev Hematol; 2022 Oct; 15(10):943-950. PubMed ID: 36000620
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes of low-dose pharmacokinetic-guided extended half-life versus low-dose standard half-life factor VIII concentrate prophylaxis in haemophilia A patients.
Rakmanotham A; Moonla C; Sosothikul D
Haemophilia; 2023 Jan; 29(1):156-164. PubMed ID: 36409282
[TBL] [Abstract][Full Text] [Related]
17. Budget impact analysis of Jivi (damoctocog alfa pegol, Bay 94-9027) in severe hemophilia A in Japan.
Fujii T; Kidoguchi Y; Takahashi N; Yu E; Ainiwaer D; Byrne A
J Med Econ; 2021; 24(1):218-225. PubMed ID: 33459088
[TBL] [Abstract][Full Text] [Related]
18. Targeting an elevated FVIII level using personalized rurioctocog alfa pegol prophylaxis in specific patient populations with hemophilia A:
Escuriola-Ettingshausen C; Klamroth R; Escobar M; Stasyshyn O; Tangada S; Engl W; Honauer I; Lee HY; Chowdary P; Windyga J
Ther Adv Hematol; 2023; 14():20406207231178596. PubMed ID: 37465396
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Real-World Dose and Consumption for Two Extended Half-Life Recombinant Factor VIII Products for the Treatment of Hemophilia A in the United States.
Wu Y; Sun SX; Fan T
J Blood Med; 2022; 13():517-524. PubMed ID: 36188439
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial.
Lentz SR; Janic D; Kavakli K; Miljic P; Oldenburg J; C Ozelo M; Santagostino E; Suzuki T; Zupancic Šalek S; Korsholm L; Matytsina I; Tiede A
Haemophilia; 2018 Nov; 24(6):e391-e394. PubMed ID: 30402994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
